These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35487526)

  • 1. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
    Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
    BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
    Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
    BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II).
    PelvEx Collaborative
    BJS Open; 2021 May; 5(3):. PubMed ID: 34089596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
    Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
    BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
    Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
    Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
    Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
    BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
    Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
    BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
    Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
    BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total neoadjuvant therapy followed by a watch-and-wait strategy for patients with rectal cancer (TOWARd): protocol for single-arm phase II/III confirmatory trial (JCOG2010).
    Hashimoto T; Tsukamoto S; Murofushi K; Ito Y; Hirano H; Tsukada Y; Sasaki K; Mizusawa J; Fukuda H; Takashima A; Kanemitsu Y
    BJS Open; 2023 Nov; 7(6):. PubMed ID: 37931233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches.
    Bach SP;
    Colorectal Dis; 2022 May; 24(5):639-651. PubMed ID: 35114057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
    Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
    BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    Huang CY; Bai MH; Shen JW; Sun QQ; Feng YR; Chen QP; Mao W; Ju HX; Zhu J
    BMC Cancer; 2024 Jan; 24(1):57. PubMed ID: 38200410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.
    Hudson EM; Noutch S; Webster J; Brown SR; Boele FW; Al-Salihi O; Baines H; Bulbeck H; Currie S; Fernandez S; Hughes J; Lilley J; Smith A; Parbutt C; Slevin F; Short S; Sebag-Montefiore D; Murray L
    BMJ Open; 2024 Mar; 14(3):e078926. PubMed ID: 38458809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.
    Kim MJ; Lee DW; Kang HC; Park JW; Ryoo SB; Han SW; Kim KS; Chie EK; Oh JH; Jeong WK; Kim BH; Nam EM; Jeong SY
    BMC Cancer; 2023 Aug; 23(1):734. PubMed ID: 37553666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial).
    Pang K; Yang Y; Tian D; Zeng N; Cao S; Ling S; Gao J; Zhao P; Wang H; Kong Y; Zhang J; Chen G; Deng W; Bai Z; Jin L; Wu G; Zhu D; Wang Y; Zhou J; Wu B; Lin G; Xiao Y; Gao Z; Ye Y; Wang X; Li A; Han J; Yao H; Yang Y; Zhang Z
    BMJ Open; 2023 Sep; 13(9):e069499. PubMed ID: 37699634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
    Zhang H; Li Y; Xia F; Sun Y; Shen L; Wan J; Chen Y; Wang Y; Zhou M; Wu R; Zhou S; Wang Y; Liu F; Cai S; Zhang Z
    BMJ Open; 2024 Feb; 14(2):e079442. PubMed ID: 38309748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.